Quell Therapeutics Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Quell Therapeutics Limited
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.
GentiBio closed a $157m series A venture capital round, while clinical trial innovator Reify Health raised a $220m series C and Neurelis secured $150m. Also, IPOs slowed in August, but Adagio and Eliem grossed $309.4m and $80m, respectively, and RNA firm Greenlight will go public in a $282m SPAC deal.
Investors keep piling into biotech stocks and British companies have been reaping the benefits this week.
- Gene Therapy, Cell Therapy